Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
have you talked with Natalie about the radiogel option for her fighting against brain cancer? If the fund collected from donation will support her pursue the choice of radiogel as treatment, that would be great!
for sure your estimation was not right, current pps was factored already by the ongoing increment of OS. BASED ON the potential of RDGL, current PPS WAS MUCH UNDERVALUED.
nice post, and basically very positive, can you post the facts links you found about the inventor Dr. Fisher?
by the way nobody can predict the potential of vivos right now about its path? things can happen sooner or later.
radiotherapy is widely used for treating cancer, there are no significant response differences among individuals.if there is way to deliver the radiogel with minimum invasive damage, it would work in controlling cancer, and improving life quality.
this is great!
hope Natalie take serious thoughts on this radiogel as potential and powerful choice, and pray this treatment can work out for her.
this board is best board I have joined, people loves to support and not only profit centered
great Job, Thank you for doing this for her best heal.
This is great support
Wow, this is great!, Vivos is doing good things!!!
https://twitter.com/radiogel
Wow. Inspiring story. Inoperable localized brain tumors are one of the highest priority #cancers that we plan on targeting with #RadioGel. We’re exploring the #RightToTry Law on how we may become an active participant. Way to fight Natalie. #CancerResearch #CancerAwareness
THAT IS RIGHT! MANAGEMENT TEAM IS TOP ONE! CONSULTANTS ARE GOOD ONES, and All treatments are being done by good universities and pets clinics!
Thank you for this estimation, however from now on good news can happen any day! Big pharma or partner they are smart, they would like to get in before approval by FDA!
Y-90
https://en.wikipedia.org/wiki/Yttrium-90
y-90 undergoes ß- decay to zirconium-90 with a half-life of 64.1 hours[4] and a decay energy of 2.28 MeV.[5] It also produces 0.01% 1.7 MeV[6] photons along the way. Interaction of the emitted electrons with matter can lead to Bremsstrahlung radiation.
Production
Yttrium-90 is a decay product of strontium-90 which makes up about 5% of the nuclear daughter isotopes when uranium is fissioned.[7][not in citation given] Yttrium-90 is produced by chemical high-purity separation from strontium-90, a fission product of uranium in nuclear reactors.[8]
Medical application
90Y plays a significant role in the treatment of hepatocellular carcinoma (HCC) and other liver cancers. Trans-arterial radioembolization is a procedure performed by interventional radiologists in which microspheres are impregnated with 90Y and injected into the arteries supplying the tumor.[9] Radioembolization with 90Y significantly prolongs time-to-progression (TTP) of HCC,[10] has a tolerable adverse event profile, and improves patient quality of life more than do similar therapies.[11]
Why why why!!!
Y-90 proved being used in human treatment
PLGA polymer was used in human treatment also,
why radiogel comprises of Y-90 and PLGA can not be approved soon?
after Dog's treatment completed, this would be done soon!
https://www.mdpi.com/2073-4360/9/6/189/pdf
PLGA, a synthetic copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA), has been adopted in the production of various therapeutic devices including tissue grafts, surgical sutures, bone tissue engineering scaffolds, and drug carrier systems [16–19] due to their excellent biocompatibility, controllable biodegradability, tunable degradation rates, mechanical properties, and thermal processibility [20,21].
PLGA has been approved by the U.S. Food and Drug Administration (FDA) for human treatment and they can be easily prepared into versatile formulations, such as membranes, scaffolds, hydrogels, nanoparticles, microparticles, and sponges.
Agreed no more!!!
Investing Is The Ultimate Case Of FOMO: Give Your Future A Chance, But in comfortable risk zone you can handle with
That is right about their integrity and authenticity
great and can someone contact company for those questions!!! But anyway, good things are on the way!!!
independent analyst coverage report, a year ago but full of facts and info about the future of the RDGL
http://nebula.wsimg.com/4428bdde9198e981707684ab50fbc9d6?AccessKeyId=F1B3D293B900048B2E3E&disposition=0&alloworigin=1
Thoughtful guess but nobody really knows! before approval for human, highly possible there will have partnership or buyout
not clear, where did you get this info
that is medically proved! much better than mouse test preclinically!
Can you kindly send me your contact privately? I would like to learn more from you since you are well-respected in mOTC investment.
Surely it is cheap! Nobody can steal my shares. got in another 10k
$RDGL$,Meet the Biotech Company About to Turn the 120-Year-Old Cancer Radiation Industry on Its Head
Vivos Inc., a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation.
is this stock OS 1000M, and no further dilution assured? thanks
The first dog treatment addressed the principal questions raised by FDA review panel, with additional dogs being treated well, the clinical approval for radiogel for human will be soon.
Richland, WA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful
Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, is pleased to report several significant outcomes after its signature product, IsoPet®, was used to treat a hind-leg soft-tissue sarcoma in a Sheltie at the University of Missouri Veterinary Health Center in Columbia, Missouri.
Veterinary oncologist, Dr. Charles Maitz, reported that the treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery. Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Kentucky, October 17 – 20, 2018.
After therapy the pet owner commented that the dog had more energy than she can remember for a long time. “The owner is delighted!” said Dr. Maitz.
Study investigators were also pleased that IsoPet® met all RadioGel™ design performance criteria. Post-treatment imaging and dosimetry provided confirmatory data addressing the principal questions previously raised by an FDA review panel, including:
1. Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues;
2. Very high therapeutic ratios (radiation dose to the tumor relative to normal organs), Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues
The University of Missouri is now advertising availability of IsoPet® treatment for dogs and other species, including treatment of equine (horse) sarcoids.
Mike Korenko, Vivos Inc CEO stated “The successful treatment of the cat and dog subjects thus far increases the likelihood of IsoPet® becoming a practical solution in the treatment of animal cancer. Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that RadioGel™ can be safe and effective for treating various human cancers.”
A great sum of how RDGL engaging FDA for clinical approval for Radiogel usage in the fighting against human cancers
well said, great job, I would add some points:
1 the polymer gel used for delivering and immobilizing Y90 was PLGA-PEG,which was approved for many medicine formulation;
2 great improvement for radiotherapy, which supposedly has no species response differences
3 outpatient procedure, has no harm or concerns when people takes care of patient
Great! I have faith in this company and will hold until see the final line!
At least 1 dollar a share!
I am holding and continue buying when that happens. but it won't be
there are lots of smart buyer
What a good way to shake out the weak! it will be on fire after a night!!!
please be respectful to a real company doing great things for pets and Human ourselves!!!
SUCH A BIPOLAR!!! IT WILL RAGE SKYROCKETED. Manipulation is in play
great management!!!Real company disrupting new tech prouducts
Agreed, as working in pharma research, those cases are not unusual
haha, we are buying a lot
Steps to treatment trials in Human
Jan-2018
https://globenewswire.com/news-release/2018/01/30/1314373/0/en/Vivos-Receives-FDA-Confirmation-of-RadioGel-Device-Classification-for-Animal-Skin-Cancer-Therapy.html
Step 1 finished:
After four months of dialog with the Center for Veterinary Medicine Product Classification Group we received a ruling that RadioGel is classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas.
Step 2 finished
The Company’s feline sarcoma therapy series at Washington State University was completed in January. Those tests were designed to optimize our procedures and to determine the optimum dose. The tests demonstrated that RadioGel™ is safe and effective in killing cancer cells.
Step 3 ongoing with five dog serial:, 1 dog healed, one dog just dosed
In February, we plan to start recruiting canine skin cancer patients to be treated at the University of Missouri, incorporating lessons learned at WSU.
Step 4: communicate with FDA about the animal therapy data, ongoing when individual data available
The animal therapy data generated from these studies will also be used in the pre-clinical data required by the FDA as part of the testing required for treating skin cancer in humans.
Step 5: when all the test finished, permission to initiate human clinical trials will be approved soon
After all the pre-clinical testing is completed we will submit an Investigational Device Exemption to obtain permission to initiate human clinical trials.
other tests in animal started In April
we plan to begin therapy at University of California Davis on canine prostate and liver cancers. Later, we will continue our testing at the University of Missouri to treat equine sarcoids.
As we expand the indications for use of IsoPet™ we intend to communicate with the FDA to confirm the device designation applies. Having established a precedent for classification of skin cancer therapy as a device makes it highly likely that subsequent cancers will also be ruled similarly. Obtaining FDA approval in stages should increase the probability of success and provide the fastest path to commercializing our product in the animal sector.
We continue to communicate our progress with potential strategic partners.
In the future, we anticipate interacting with their technical review teams to assess the results of our animal therapies and endorse our product. We will then determine the optimum business relationship to sell IsoPet™, with the goal of leveraging the broad national presence of our strategic partner.
Dr. Mike Korenko stated “Obtaining this approval is an important step to set the stage for selling IsoPet to the private clinics for animal therapy. By being labeled a device there are no other regulatory approvals necessary for treating skin cancer, the most common cancer in animals. We chose a conservative path of obtaining FDA classification early with full and open communication on our intent in order to remove any future uncertainty in the regulatory space.”
Thank you DrugD, it is reasonable!
Dog is more similar than any other species common species to human for preclinical tests. Very careful proves in dogs pave it way towards human cancer treatment.
just curiously ask, what is the level 2? what does that mean? how to review or check it